GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Evonile Pharma Ltd

Evonile Pharma Q2 FY27: Clarifies ₹800 Crores Total Financial Indebtedness

RESULTS ● No Immediate Change LOW RISK
📅 Filed on BSE: 04 Nov 2026, 12:08 AM IST  ·  BSE ID: d2d1debf-c4ab-4c04-a084-74d963bae827
View Original BSE Filing (PDF)
💡
In Simple Terms
Evonile Pharma revised its latest financial report to confirm ₹800 Crores in total debt, with no defaults.
🤖 AI Summary
  • Evonile Pharma submitted a revised integrated financial filing for Q2 FY27 to rectify a heading omission.
  • The company clarified total financial indebtedness as ₹800 Crores as on September 30, 2026.
  • Outstanding loans/revolving facilities from banks/financial institutions totaled ₹800 Crores.
  • No amount of default was reported on loans/debt securities as of September 30, 2026.
  • All other disclosures in the earlier Q2 FY27 financial results filing remain unchanged.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Total amount outstanding from Loans / revolving facilities (Q2 FY27)
₹800 crores
Amount of default as on date (Q2 FY27)
Nil
Total financial indebtedness (Q2 FY27)
₹800 crores
🏢 How This Affects the Company
💰
Financial Impact
The clarification confirms the company's financial indebtedness at ₹800 Crores as of September 30, 2026, with no reported defaults on this debt.
⚠️
Risk Impact
The filing reduces ambiguity regarding the company's debt position by explicitly stating the total financial indebtedness as ₹800 Crores.
👥 What This Means For Shareholders
✅
Action Required
No action required based on this specific clarification filing.
👤
Who Is Affected
All shareholders are affected by clear financial reporting, ensuring accurate understanding of the company's debt obligations of ₹800 Crores.
🔍
Management Signal
Management is signaling a commitment to transparent and accurate financial reporting by promptly rectifying an omission in a previous filing.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 financial results — review debt levels and financial indebtedness.
Future related party transactions disclosures — monitor value and nature of transactions.
Any further regulatory filings regarding debt or financial statements.
LOW RISK The filing is a clarification correcting an omission, not indicating new financial risk.
💡 Investor Takeaway
Evonile Pharma Limited confirmed its total financial indebtedness as ₹800 Crores as on September 30, 2026, for Q2 FY27. This includes ₹800 Crores outstanding from bank/financial institution loans. The company reported Nil defaults on any loans or debt securities.
⚖️ Strengths & Concerns

✅ Positives

  • Confirmed Nil amount of default on loans/debt securities as on September 30, 2026.
  • Clarification explicitly states total financial indebtedness as ₹800 Crores, removing previous ambiguity.
📅 Company Track Record
Evonile Pharma (formerly Novartis India Limited) reported Q2 FY27 revenue of ₹56.1 crore and Operating EBITDA of -₹31.8 crore in previous filings. The company has consistently reported Nil total financial indebtedness in Q1 FY27, though this current filing reports ₹800 crores for Q2 FY27.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What is Evonile Pharma's total financial indebtedness for Q2 FY27?
Evonile Pharma's total financial indebtedness, including short-term and long-term debt, is clarified as ₹800 crores as on September 30, 2026.
Did Evonile Pharma report any defaults on loans or debt securities for Q2 FY27?
No, Evonile Pharma reported 'Nil' amount of default on loans and debt securities as on September 30, 2026.
What was the amount outstanding from bank loans/revolving facilities for Evonile Pharma in Q2 FY27?
The total amount outstanding from loans/revolving facilities like cash credit from banks/financial institutions for Evonile Pharma was ₹800 crores as on September 30, 2026.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.